PL3345904T3 - Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych - Google Patents

Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych

Info

Publication number
PL3345904T3
PL3345904T3 PL18156043T PL18156043T PL3345904T3 PL 3345904 T3 PL3345904 T3 PL 3345904T3 PL 18156043 T PL18156043 T PL 18156043T PL 18156043 T PL18156043 T PL 18156043T PL 3345904 T3 PL3345904 T3 PL 3345904T3
Authority
PL
Poland
Prior art keywords
compounds
agonist activity
beta2 adrenergic
receptor antagonist
receptor agonist
Prior art date
Application number
PL18156043T
Other languages
English (en)
Inventor
Fabio Rancati
Ian Linney
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3345904T3 publication Critical patent/PL3345904T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18156043T 2012-12-06 2013-12-05 Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych PL3345904T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12195891 2012-12-06
EP13811827.8A EP2928889B1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP18156043.4A EP3345904B1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PCT/EP2013/075661 WO2014086924A1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number Publication Date
PL3345904T3 true PL3345904T3 (pl) 2020-12-14

Family

ID=47323975

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13811827T PL2928889T3 (pl) 2012-12-06 2013-12-05 Związki wykazujące aktywność antagonisty receptorów muskarynowych i aktywność agonisty receptorów beta-2 adrenergicznych
PL18156043T PL3345904T3 (pl) 2012-12-06 2013-12-05 Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13811827T PL2928889T3 (pl) 2012-12-06 2013-12-05 Związki wykazujące aktywność antagonisty receptorów muskarynowych i aktywność agonisty receptorów beta-2 adrenergicznych

Country Status (37)

Country Link
US (2) US8987299B2 (pl)
EP (2) EP3345904B1 (pl)
JP (1) JP6421989B2 (pl)
KR (2) KR102240459B1 (pl)
CN (1) CN104822678B (pl)
AR (1) AR093825A1 (pl)
AU (1) AU2013354043C1 (pl)
BR (1) BR112015012730B1 (pl)
CA (1) CA2893626C (pl)
CL (1) CL2015001483A1 (pl)
CO (1) CO7400870A2 (pl)
CY (2) CY1120159T1 (pl)
DK (2) DK2928889T3 (pl)
EA (1) EA030552B1 (pl)
ES (2) ES2670686T3 (pl)
GE (1) GEP20186839B (pl)
HR (2) HRP20180915T1 (pl)
HU (2) HUE051394T2 (pl)
IL (1) IL239182B (pl)
LT (2) LT2928889T (pl)
MA (1) MA38147B1 (pl)
MX (1) MX369311B (pl)
NZ (1) NZ708738A (pl)
PE (1) PE20151216A1 (pl)
PH (1) PH12015501247B1 (pl)
PL (2) PL2928889T3 (pl)
PT (2) PT3345904T (pl)
RS (2) RS60864B1 (pl)
SA (1) SA515360514B1 (pl)
SG (2) SG10201704032RA (pl)
SI (2) SI2928889T1 (pl)
TN (1) TN2015000244A1 (pl)
TR (1) TR201808698T4 (pl)
TW (1) TWI637954B (pl)
UA (1) UA118181C2 (pl)
WO (1) WO2014086924A1 (pl)
ZA (1) ZA201503965B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
SG10201704032RA (en) * 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
HUE056260T2 (hu) * 2015-11-16 2022-02-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en) 2017-11-06 2024-01-23 Entech Solution As Method and stimulation sleeve for well completion in a subterranean wellbore
EP4365162A3 (en) * 2020-12-21 2024-10-09 Intervet International B.V. A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222128A (en) 1937-01-29 1940-11-19 Pure Oil Co Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
ME00557A (en) 2004-01-22 2011-12-20 Sulfonamide derivatives for the treatment of diseases
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
CA2760630A1 (en) * 2009-04-30 2010-11-04 Teijin Pharma Limited Quaternary ammonium salt compounds
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
BR112013031493B1 (pt) * 2011-06-10 2022-04-19 Chiesi Farmaceutici S.P.A Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
SG10201704032RA (en) * 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物

Also Published As

Publication number Publication date
KR102156443B1 (ko) 2020-09-17
LT3345904T (lt) 2020-09-25
IL239182A0 (en) 2015-07-30
EA030552B1 (ru) 2018-08-31
PE20151216A1 (es) 2015-09-08
SA515360514B1 (ar) 2016-08-30
ES2816210T3 (es) 2021-03-31
TR201808698T4 (tr) 2018-07-23
EP3345904B1 (en) 2020-07-29
RS57232B1 (sr) 2018-07-31
CN104822678B (zh) 2017-03-08
CA2893626A1 (en) 2014-06-12
KR20200027049A (ko) 2020-03-11
CN104822678A (zh) 2015-08-05
MA38147B1 (fr) 2018-09-28
GEP20186839B (en) 2018-04-10
AU2013354043C1 (en) 2017-08-31
JP6421989B2 (ja) 2018-11-14
US9371318B2 (en) 2016-06-21
EP3345904A1 (en) 2018-07-11
ZA201503965B (en) 2016-09-28
CA2893626C (en) 2021-08-24
IL239182B (en) 2018-12-31
SG10201704032RA (en) 2017-06-29
EP2928889A1 (en) 2015-10-14
US8987299B2 (en) 2015-03-24
SI3345904T1 (sl) 2020-09-30
MX369311B (es) 2019-11-05
PH12015501247A1 (en) 2015-08-17
PL2928889T3 (pl) 2018-09-28
SI2928889T1 (en) 2018-05-31
UA118181C2 (uk) 2018-12-10
ES2670686T3 (es) 2018-05-31
RS60864B1 (sr) 2020-11-30
US20150133491A1 (en) 2015-05-14
DK2928889T3 (en) 2018-05-22
TWI637954B (zh) 2018-10-11
PT2928889T (pt) 2018-05-29
HUE037944T2 (hu) 2018-09-28
JP2016502557A (ja) 2016-01-28
AR093825A1 (es) 2015-06-24
AU2013354043B2 (en) 2017-06-15
HK1212989A1 (zh) 2016-06-24
MX2015006788A (es) 2015-08-05
CL2015001483A1 (es) 2015-10-23
TW201427976A (zh) 2014-07-16
PH12015501247B1 (en) 2019-02-06
MA38147A1 (fr) 2018-03-30
KR20150090108A (ko) 2015-08-05
BR112015012730B1 (pt) 2022-07-05
NZ708738A (en) 2019-02-22
US20140161736A1 (en) 2014-06-12
HUE051394T2 (hu) 2021-03-01
CY1120159T1 (el) 2018-12-12
WO2014086924A1 (en) 2014-06-12
CO7400870A2 (es) 2015-09-30
CY1123365T1 (el) 2021-12-31
BR112015012730A2 (pt) 2017-07-11
EP2928889B1 (en) 2018-03-21
PT3345904T (pt) 2020-09-07
HRP20180915T1 (hr) 2018-07-27
TN2015000244A1 (en) 2016-10-03
EA201590873A1 (ru) 2015-09-30
SG11201504318UA (en) 2015-07-30
LT2928889T (lt) 2018-06-11
DK3345904T3 (da) 2020-08-31
KR102240459B1 (ko) 2021-04-16
HRP20201435T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
PL2928890T3 (pl) Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
ZA201503965B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ZA201309242B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR20180085068A (ko) 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
IL215554A0 (en) Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PT2776425T (pt) Novos derivados de ciclo-hexilamina que possuem atividades agonista adrenérgica β2 e antagonista muscarínica m3
SMT201700022T1 (it) NUOVI DERIVATI DELLA CICLOESILAMMINA AVENTI ATTIVITÀ DI AGONISTA β2 ADRENERGICO E ANTAGONISTA MUSCARINICO M3
IL239118A0 (en) New cyclohexyl and quinoclidinyl carbamate compounds with beta-2 adrenergic agonistic and m3 muscarinic antagonistic activity
ZA201705376B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
IL236702A0 (en) 5–ht3 receptor antagonists